European strategy for vaccine development against infectious diseases

Matthiessen, Line; Lång, Hannu; Klimathianaki, Maria; Hanrahan, Finnian; Kerstiëns, Barbara; Martini, Alessandra Cadete; Draghia-Akli, Ruxandra

doi:10.1016/j.vaccine.2016.10.031

Cited by 5 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The recent results also require important decisions that will shape the next generation of clinical trials to address critical knowledge gaps and unequivocally demonstrate the public health value of new TB vaccination strategies for endemic countries. The size and scope of future TB vaccine efficacy trials will require consortia of public and private funders (Matthiessen et al, 2017), concerted political will, and as the centenary of BCG vaccination approaches, an urgent plan of action from the TB vaccine stakeholder community to achieve End TB targets (Uplekar et al, 2015).…”

Section: Resultsmentioning

confidence: 99%

Clinical Development of New TB Vaccines: Recent Advances and Next Steps

2020

View full text Add to dashboard Cite

Mycobacterium tuberculosis (Mtb) kills more people worldwide than any single infectious pathogen, yet the only vaccine licensed against tuberculosis, Bacille Calmette Guerin (BCG) is approaching its centenary. Two recent advances in clinical tuberculosis vaccine development have invigorated the field. BCG revaccination of interferon-gamma release assay (IGRA) negative adolescents provided 45% protection against sustained Mtb infection defined by IGRA conversion; and the protein-subunit vaccine M72/AS01 E provided 50% protection against progression from Mtb infection to tuberculosis disease in IGRA-positive adults. These findings provide encouraging evidence for pre-exposure and post-exposure approaches to vaccination against tuberculosis, both of which may be necessary to rapidly interrupt the cycle of Mtb transmission and sustain long-term impact on global tuberculosis control. New trials are needed to demonstrate efficacy of M72/AS01 E with greater precision, in a wider age range, in diverse epidemic settings, and in populations that include Mtb-uninfected and HIV-infected persons. Modeling the impact of mass campaigns with M72/AS01 E and other fast-follower vaccine candidates will be crucial to make the use case and demonstrate public health value for TB endemic countries. The size and scope of the next generation of efficacy trials, and the need to expand and accelerate the existing clinical development pipeline, will require public and private consortium funding and concerted political will.

show abstract

Section: Resultsmentioning

confidence: 99%

Clinical Development of New TB Vaccines: Recent Advances and Next Steps

2020

View full text Add to dashboard Cite

show abstract

“…The controversy sweeping across Europe about rights and duties in respect of vaccination offers a compelling example: many parents, unconvinced of the merits of vaccination for their child, are withholding permission for the conduct of immunisation procedures. Here the contrast between private and public interests is also clear, as an individual's insistence on refusing vaccination clashes with the public benefit of herd protection that vaccination affords [20]. …”

Section: Innovation and Healthcarementioning

confidence: 99%

Keeping the Person in Personalised Healthcare

Horgan¹

2017

Biomed Hub

View full text Add to dashboard Cite

Proponents of personalised medicine believe that the involvement of the patients, including in “risk-sharing agreements,” will result in cost savings, the use of the genetic makeup of an individual patient as the starting point will save resources and, indirectly, there will be great potential for startups and new business in many areas. But how can Europe ensure that the “person” is central stage and allow us to focus on the development of personalised medicine for his or her ultimate benefit? The EU has a clear role to play, argues the author. One way for this to happen is for the EU to focus investment in guidelines for governance. This will go a long way to ensuring that the citizen is the principal factor when it comes to utilising the new wealth of innovation in health. The citizen must always come first when innovation is harnessed.

show abstract

“…As a result, there is a global focus on selecting and supporting novel vaccines, ensuring vaccine implementation in countries with weak healthcare systems, providing vaccines for all age groups, and committing to sustainable development (Matthiessen et al, 2017).…”

Section: Introductionmentioning

confidence: 99%

Analysis of driving factors influencing vaccine policy in Iran: a cross-impact analysis

Moradi-Lakeh,

Goharinezhad,

Amirkafi

et al. 2024

View full text Add to dashboard Cite

Purpose Despite significant progress in Iran's immunization programs, vaccine policymaking in the country still faces various challenges and shortcomings. To address these issues and ensure sustained progress toward achieving comprehensive vaccination policies, it is essential to identify the critical factors influencing vaccine policies in Iran. Our study aims to provide evidence-based insights that can inform the development of effective and equitable vaccine strategies, leading to a more sustainable and efficient approach to vaccination in the country. Design/methodology/approach This mixed-method study aimed to analyze the factors influencing the future of human vaccine policy using Cross Impact Analysis. Firstly, a scoping review was conducted to identify the factors affecting the future of human vaccine development. Secondly, a semi-structured interview was conducted with experts in this field to add more factors and confirm the identified factors within the Iranian context. Finally, a Cross-Impact Analysis (CIA) approach was applied to comprehend the complex relationships between the identified factors. Thematic analysis was used for the qualitative data, and MICMAC analysis was applied to characterize the relationships between the factors. Findings Seventeen key driving force factors were identified through comprehensive review and interviews. These factors were assigned weighted values ranging from zero to three and subsequently analyzed using MICMAC software. Employing the Cross-Impact Analysis (CIA) technique, the study characterized the impact of each factor on vaccine policy and elucidated the intricate interactions between them. The findings underscored that robust leadership and governance, an innovative ecosystem, and well-established immunization information systems emerged as pivotal driving forces shaping vaccine policy in Iran. Research limitations/implications While this study contributes valuable insights into the driving factors influencing vaccine policy in Iran, it is important to acknowledge several limitations. The results rely on the subjective perceptions of a diverse group of specialists, and future research could delve into additional factors in other countries to identify common themes and differences. Practical implications This study provides evidence to assist policymakers in making informed decisions regarding vaccines in Iran. The findings suggest that enhancing access to vaccines, fostering trust in the healthcare system, and prioritizing equity in distribution can contribute to increased vaccination rates and a reduction in vaccine-preventable diseases. Originality/value This study provides a unique contribution to the field of vaccine policy by utilizing the cross-impact analysis to examine the complex interactions among various factors. The results of this analysis demonstrate that these interactions can significantly impact the overall system, highlighting the need for policymakers to consider multiple factors when formulating effective strategies. By revealing the significance of these interactions, this research offers valuable insights into the development of successful policies that can shape a desirable future for vaccine policy in Iran. Future studies could ratify the findings from this research by applying other methodological approaches.

show abstract

European strategy for vaccine development against infectious diseases

Cited by 5 publications

References 7 publications

Clinical Development of New TB Vaccines: Recent Advances and Next Steps

Clinical Development of New TB Vaccines: Recent Advances and Next Steps

Keeping the Person in Personalised Healthcare

Analysis of driving factors influencing vaccine policy in Iran: a cross-impact analysis

Contact Info

Product

Resources

About